• In patients with chronic kidney disease, dietary sodium restriction reduced albuminuria (an indicator of kidney dysfunction) and blood pressure, whereas paricalcitol (a vitamin D receptor activator) in itself had no significant effect on these measures. • The combination of paricalcitol and a low sodium diet resulted in the lowest albuminuria levels in patients.
In mouse experiments, researchers have shown how aging and excess dietary fat create signals that lead to heart failure after a heart attack. Clarifying the mechanism of this harmful pathway is important because nearly 5 million people in the United States suffer heart failure as an age-related disease following heart attacks.
As conventional fee-for-service models become less viable, cardiologists will need to participate in emerging payment models, according to a review published by GW researcher Steven Farmer, M.D., Ph.D., in the Journal of the American Medical Association Cardiology.
A newer generation left ventricular assist device (LVAD) provides better outcomes for patients with advanced heart failure at six months compared to its predecessor, according to a new study. Researchers presented data from the MOMENTUM 3 trial at the 2016 Scientific Sessions of the American Heart Association and also co-published in the New England Journal of Medicine.
New research from Saint Louis University finds that the prices for commonly used generic heart failure drugs varies widely.
Cedars-Sinai health investigators will use a $1.2 million grant from a state precision medicine initiative to design a system using remote monitoring to predict heart attacks and other cardiovascular events. In this study, the research team will look for the earliest signs of cardiovascular disease by monitoring patients remotely with a specialized watch that measures activity, sleep, heart rate and stress levels.
Atrial fibrillation patients who use the drug, warfarin, to prevent harmful blood clots from forming in their hearts to lower risk of stroke are at higher risk of developing dementia than patients who use warfarin for non-atrial fibrillation conditions, according to a new study from the Intermountain Medical Center Heart Institute.
The prospect of creating artery “banks” available for cardiovascular surgery, bypassing the need to harvest vessels from the patient, could transform treatment of many common heart and vascular ailments. But it’s a big leap from concept to reality.
When patients suffer from atrial fibrillation, an irregular heartbeat, they are at considerably higher risk for blood clots and stroke. However, when hospitalized, half of these patients do not receive medications that could help prevent such complications, according to research being presented Nov. 14 at the American Heart Association Scientific Sessions.
A new study led by clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) testing the safety and effectiveness of anticoagulant strategies for patients with atrial fibrillation who undergo stenting procedures has shown that therapies combining the anticoagulant drug rivaroxaban with either single or dual anti-platelet therapy (DAPT) were more effective in preventing bleeding complications than the current standard of care.
Many people who experience chest pain but don’t have a heart attack breathe a big sigh of relief when a stress test comes back negative for blockages in their blood vessels. But a new study by cardiac researchers at the Intermountain Medical Center Heart Institute in Salt Lake City found they may not be off the hook after all.
Research published by a Houston Methodist team led by John Cooke, M.D., Ph.D., received high accolades at this year’s American Heart Association Scientific Sessions.
The Mount Sinai Health System and Healthfirst are, for the third year, teaming up to provide their co-branded Medicare Advantage plan for Manhattan residents — the Healthfirst Mount Sinai Select (HMO) plan — during the Medicare Annual Enrollment Period.
Depression has been known to be associated with poor cardiovascular outcomes, but if patients who are depressed attend cardiac rehabilitation after heart surgery, their risk of death is significantly reduced, according to a new study.
Two differing blood clot prevention medications are just as safe and effective for patients undergoing percutaneous coronary intervention, a non-surgical procedure to open blood vessels narrowed by plaque buildup, according to a new study.
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation to treat the abnormal heart rhythm lower their long-term risk of a recurrent stroke by 50 percent, according to new research from the Intermountain Medical Center Heart Institute
While patients with inflammatory rheumatic diseases such as RA or spondyloarthritis are at increased risk for CVD, too few are prescribed preventive medications or meeting target goals to prevent heart-related events, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
The worldwide cardiothoracic surgery community is aware of the public health issue with recent heater-cooler infection findings traced to a manufacturing facility and has actively engaged in understanding the cause and developing measures to lower the risk and occurrences of these infections.
The Cardiovascular Research Foundation (CRF) announced that it will launch a new international journal focusing on the diagnosis and treatment of structural heart disease and the importance of the heart team in managing these disorders.
Physicians, fellows, and researchers from Mount Sinai Health System are presenting late-breaking clinical trials and research updates at the American Heart Association’s Scientific Sessions in New Orleans, LA, November 12-15, 2016.
African-Americans have more rigidity of the aorta, the major artery supplying oxygen-rich blood to the body, than Caucasians and Hispanics, according to a study by UT Southwestern Medical Center cardiologists.
A new study finds that heart surgery patients’ chances of survival depends in part on the overall previous level of teamwork among all the physicians who cared for them across their surgery preparation, operation, hospitalization and recuperation.
A new study of patients treated with intensive statin therapy reveals intracoronary imaging evidence of plaque stabilization associated with improved cholesterol transport and distinct transcriptomic perturbations
Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin strut sirolimus-eluting stents (Osiro SES) with a biodegradable polymer compared to thin-strut everolimus-eluting stents (Xience EES) with a durable polymer in terms of in-segment late lumen loss in successfully treated chronic total occlusions. In addition, although the rate of binary restenosis was low overall in this complex lesion subset, it was higher with the Osirio SES compared with the Xience EES.
Results from the U.S. real-world, post-FDA approval experience of the Watchman device found high procedural success and low complication rates despite implantations by a large percentage of new operators. The Watchman device was approved by the U.S. Food and Drug Administration (FDA) in March 2015 for left atrial appendage occlusion (LAAC) to reduce the risk of stroke in patients with non-valvular atrial fibrillation (AF).
Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OCT) to evaluate strut coverage and neoatherosclerosis (NA) found that bioresorbable polymer-based drug-eluting stents (BP-EES) are comparable to durable polymer-based drug-eluting stents (DP-ZES).
To better understand why some people adapt well to life at high altitude while others don’t, researchers at University of California San Diego School of Medicine studied red blood cells derived from representatives of both groups living in the Andes Mountains. The study reveals that high-altitude, low-oxygen dwellers prone to chronic mountain sickness produce massive amounts of red blood cells thanks to overproduction of the enzyme SENP1.
The CardioVascular Institute (CVI) at Beth Israel Deaconess Medical Center (BIDMC) has transformed the delivery of cardiac care with the opening of the new Cardiac Direct Access Unit (CDAc). The first of its kind in New England, the outpatient unit offers immediate evaluation and care, allowing many individuals with heart conditions to avoid preventable and costly Emergency Department visits.
Women have about a 20 percent less chance of developing heart disease after weight-loss surgery than men, according to new research* presented today at ObesityWeek 2016, the largest international event focused on the basic science, clinical application and prevention and treatment of obesity. The annual conference is hosted by the American Society for Metabolic and Bariatric Surgery (ASMBS) and The Obesity Society (TOS).
During stroke or heart attack, tissue damage can be limited because “collateral” vessels connect the tissue to other arteries. Collateral vessels can vary greatly in size and number from one person to the next. Scientists have now implicated the Rabep2 gene as a major contributor to variation.
Cardiovascular disease, including heart disease and stroke, kills more than 800,000 Americans each year. We know that too much salt may contribute to high blood pressure and increased cardiovascular risk. According to a new study in the Journal of the Academy of Nutrition and Dietetics, American children are consuming sodium at levels that far exceed the daily recommended limit. Taste preferences for high sodium foods, formed as children, follow individuals into adulthood and put them at increased risk for developing cardiovascular problems later in life.
The 2016 Mount Sinai ADVANCED Heart Disease Symposium is a one-day intensive state-of-the-art review of heart failure and advanced cardiac care, consisting of didactic lectures, debates and expert panel discussions of emerging or controversial topics in heart failure, mechanical circulatory support and cardiac transplantation.
Initial results from the largest, prospective evaluation of a percutaneous transcatheter left atrial appendage (LAA) closure device (Amplatzer Amulet) for stroke prevention in patients with non-valvular atrial fibrillation show that the device has a high implant success rate and low major adverse events.
Using specialized CT scans of a healthy heart and one with heart disease, a team of Johns Hopkins cardiologists and biomedical engineers say they've created computer models of the "shape" of blood flow through the heart's upper left chamber that someday may help predict stroke risk.
A randomized evaluation of routine follow-up coronary angiography after percutaneous coronary intervention (PCI) found that there was no long-term clinical benefit compared to clinical follow-up alone among unselected patients following PCI.
A dedicated stent study conducted exclusively in women and minority patients evaluated clinical outcomes within the era of contemporary PCI, comparing these results to a parallel cohort of white male patients. Although there were no significant differences in stent-related outcomes, both groups had higher rates of death and myocardial infarction (MI) in the first year following the procedure.
Final results from the RESPECT trial found that percutaneously closing a patent foramen ovale (PFO) using the Amplatzer PFO Occluder was superior to medical management in the prevention of recurrent ischemic stroke in patients who previously had a cryptogenic stroke.
Two-year results from COLOR, the first large-scale multicenter prospective study of its kind, found that PCI on coronary artery lipid-rich plaque (LRP) detected by near infrared spectroscopy (NIRS) was not associated with subsequent major adverse cardiac events (MACE) compared to PCI of non-LRPs.
A substudy of the PARTNER I Trial and Continued Access Registry found that hemodynamic trends in patients who received transcatheter aortic valve replacement (TAVR) showed excellent durability without significant structural valve deterioration at five years. The trial represents the largest to-date longitudinal analysis of echocardiographic hemodynamic parameters systematically assessed by a core laboratory.
Patients with severe aortic stenosis (AS) at intermediate surgical risk, and who are treated with transcatheter aortic valve replacement (TAVR) had improved health status at one month compared with surgical aortic valve replacement (SAVR) but two-year quality of life outcomes were similar. Prior studies have shown that TAVR results in an early quality of life (QoL) benefit in patients at high surgical risk; however, the effect of TAVR versus. SAVR on QoL in intermediate risk patients was unknown prior to this study.
A multicenter randomized trial evaluating the role of embolic protection using the Sentinel device during transcatheter aortic valve replacement (TAVR) found that the device was safe but did not meet the primary efficacy endpoint of reduction in median new lesion volume in protected territories assessed by MRI at 2-7 days. In addition, neurocognitive function was not significantly improved.
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective capture of embolic debris and does not change neurocognitive function for transcatheter aortic valve replacement (TAVR) patients.
Officials at Johns Hopkins Medicine’s teen health program announce the launch of a new website, Y2CONNECT, designed to connect Baltimore City youth with a wide range of clinical and community-based health and non-health programs and resources.
Normal, healthy heart muscle is well-supplied with oxygen-rich blood. But UT Southwestern Medical Center cardiologists have been able to regenerate heart muscle by placing mice in an extremely low-oxygen environment.
Researchers with the UCI Susan Samueli Center for Integrative Medicine have found that regular electroacupunture treatment can lower hypertension by increasing the release of a kind of opioid in the brainstem region that controls blood pressure.
The 28th annual Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF) featured a number of first report investigations on novel stents that could become the next generation of bioresorbable stents in patients.
A first-in-human study of a new polymer-free drug-filled stent, which provides controlled drug elution from an internal lumen, indicated non-inferior in-stent late lumen loss at nine-months compared with historical zotarolimus-eluting stent (Resolute) data. In addition, there was no binary restenosis, and a high degree of early stent strut coverage with minimal malapposition.
A large-scale randomized trial examining percutaneous coronary intervention (PCI) versus coronary artery bypass graft surgery (CABG) in patients with left main coronary artery disease (LMCAD) and low-intermediate SYNTAX scores found that there was no significant difference in three-year outcomes between the two treatments, with a reduction in 30-day major adverse events with PCI.
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main coronary artery (LMCA) disease, but use of percutaneous coronary intervention (PCI) for this indication is increasing. Findings from the Nordic–Baltic–British Left Main Revascularization Study (NOBLE) trial found that despite similar mortality, the five-year risk of major adverse events was higher after PCI compared to CABG for the treatment of unprotected LMCA disease.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right